NexgenRx Inc. (TSXV:NXG)
Canada
· Delayed Price · Currency is CAD | Market Cap | 18.49M |
| Revenue (ttm) | 16.11M |
| Net Income (ttm) | 254.52K |
| Shares Out | 71.12M |
| EPS (ttm) | 0.00 |
| PE Ratio | 78.98 |
| Forward PE | n/a |
| Dividend | 0.01 (3.85%) |
| Ex-Dividend Date | Dec 16, 2024 |
| Volume | 16,500 |
| Average Volume | 6,550 |
| Open | 0.2600 |
| Previous Close | 0.2600 |
| Day's Range | 0.2600 - 0.2600 |
| 52-Week Range | 0.1900 - 0.3500 |
| Beta | 0.41 |
| RSI | 55.00 |
| Earnings Date | Mar 28, 2025 |
About NexgenRx
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers in Canada. It offers NexSys claims management; NexAdmin plan administration; and NexPSPAssist patient support programs. The company also provides ancillary services. TNexgenRx Inc. was incorporated in 2003 and is headquartered in Toronto, Canada. [Read more]
Financial Performance
In 2023, NexgenRx's revenue was 13.85 million, an increase of 8.33% compared to the previous year's 12.78 million. Losses were -331,970, 1381.9% more than in 2022.
Financial StatementsNews
NexgenRx Announces Third Quarter Results and Declaration of Divdend
TORONTO, ON / ACCESSWIRE / November 25, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the third quarter ended September 30, 2024, with quarterly r...
NexgenRX Announces Director Re-Appointment
TORONTO, ON / ACCESSWIRE / October 7, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the re-appointment of Charles Burns to its Board of Directors effective immediately.
NexgenRx Announces New Director
TORONTO, ON / ACCESSWIRE / October 1, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the appointment of Linda Brennan to its Board of Directors effective immediately.
NexgenRx Announces Second Quarter Results, With Over 19% Revenue Growth and Positive EBITDA
TORONTO, ON / ACCESSWIRE / August 15, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the second quarter ended June 30, 2024, with quarterly revenue...
NexgenRx Announces Share Issuances Under Consulting Agreement
TORONTO, ON / ACCESSWIRE / July 18, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the issuance of an aggregate of 195,312 common shares at a price of $0.32 in respect of th...
NexgenRx Announces Declaration of Dividend
NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding commo...
NexgenRx Announces First Quarter Results, with 24% Revenue Growth and Record Earnings
TORONTO, ON / ACCESSWIRE / May 17, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its financial results for the first quarter ended March 31, 2024, with revenue of $4,292,73...
NexgenRx Announces Annual Meeting Results
TORONTO, ON / ACCESSWIRE / May 16, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce the results of its annual and special meeting (the "Meeting") of shareholders, which was he...
NexgenRx Announces 2023 Year End Results With Solid Revenue Growth, Continuing Positive EBITDA
TORONTO, ON / ACCESSWIRE / April 5, 2024 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2023, with continue...
NexgenRx Announces Director Resignation
TORONTO, ON / ACCESSWIRE / December 29, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") announces the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive ro...
NexgenRX Announces Declaration of Dividend
TORONTO, ON / ACCESSWIRE / December 20, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been decl...
NexgenRx Inc. Announces Q3 2023 Quarterly Results with Continued Revenue Growth and Positive EBITDA
TORONTO, ON / ACCESSWIRE / November 23, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2023, with con...
Nexgenrx Announces Q2 2023 Quarterly Results (With Continued Revenue Growth), Consulting Agreement and Option Grant
TORONTO, ON / ACCESSWIRE / August 21, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2023, with continued...
NexgenRx Announces Q1 2023 Quarterly Results with Continued Revenue Growth and Positive EBITDA and Announces Election of New Director
TORONTO, ON / ACCESSWIRE / May 18, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the first quarter ended March 31, 2023, with revenues gro...
NexgenRx Announces 2022 Year End Results With Continued Revenue Growth And Positive EBITDA
TORONTO, ON / ACCESSWIRE / April 6, 2023 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the financial year ended December 31, 2022, once again hi...
NexgenRx Announces Q3 2022 Financial Results with Continued Revenue Growth, Positive EBITDA and Free Cash Flow
TORONTO, ON / ACCESSWIRE / November 29, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2022, highligh...
NexgenRx Announces Q2 2022 Financial Results with Continued Revenue Growth, Positive EBITDA and Increased Free Cash Flow
TORONTO, ON / ACCESSWIRE / August 18, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2022, highlighted by...
Nexgenrx Announces Q1 2022 Financial Results with Continued Growth in Net Income, EBIDTA and Revenue
TORONTO, ON / ACCESSWIRE / May 17, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") (TSXV:NXG) is pleased to announce its interim financial results for the first quarter ended March 31, 2022, highli...
NexgenRx Announces 2021 Year End Results with Significant Revenue Growth and $3.5m EBITDA
TORONTO, ON / ACCESSWIRE / March 25, 2022 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the year ended December 31, 2021, highlighted by 12.01% ...
NexgenRx Announces Financial Results for Q3 2021 with Increased Positive EBITDA and Free Cash Flow
TORONTO, ON / ACCESSWIRE / November 19, 2021 / NEXGENRX INC. ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2021.
NexgenRx Announces Expansion of Leadership Team
Addition of two senior executives, John Gray and Mark Payne to the leadership team signals continued focus on technology operations and strategic innovation partnerships TORONTO, ON / ACCESSWIRE / Aug...
NexgenRx Announces Financial Results for Q2 2021 With Continued Growth in Revenues and Adjusted EBITDA
TORONTO, ON / ACCESSWIRE / August 18, 2021 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the second quarter ended June 30, 2021, whi...
NexgenRx Announces Financial Results for Q1 2021 with Continued EBITDA and Net Profit Growth
TORONTO, ON / ACCESSWIRE / May 26, 2021 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its interim financial results for the first quarter ended March 31, 2021, which ...
NexgenRx Announces 2020 Year End Results with Record EBITDA and Net Profit
TORONTO, ON / ACCESSWIRE / March 31, 2021 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce its annual financial results for the year ended December 31, 2020, which show ...
NexgenRx Announces Retirement of all CBA/MYB Outstanding Indebtedness and Stock Option Grants
TORONTO, ON / ACCESSWIRE / March 5, 2021 / NEXGENRX INC. (TSXV:NXG) ("NexgenRx" or the "Company") is pleased to announce that it has completed payment of all deferred consideration in connection with ...